Found 20 clinical trials
A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab
The purpose of this phase I/Ib study is to determine the safety profile of NIZ985 (new formulation), and if it can be safely combined with Spartalizumab and to determine the appropriate dose and schedule for further study. Moreover, the study will characterize the pharmacokinetic profiles of NIZ985 as a single …
- 0 views
- 19 Feb, 2024
First-in-Human Dose Escalation Trial of ATRC-101 in Adults With Advanced Solid Malignancies
ATRC-101-A01 is a first-in-human, Phase 1b, open-label trial to characterize the safety, tolerability, pharmacokinetics (PK), and biological activity of escalating doses of ATRC-101, an engineered, fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally-occurring human antibody.
- 0 views
- 19 Feb, 2024
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
This study will investigate the effects of atezolizumab on select cancer types in people whose analysis of tumour DNA and RNA indicates they may be sensitive to atezolizumab. This study aims to determine if the information from the cancer genome analysis corresponds with the effects of atezolizumab on individuals and …
- 0 views
- 19 Feb, 2024
Brief Title: Study of BGB-10188 as Monotherapy and in Combination With Zanubrutinib and Tislelizumab
The purpose of this study is to determine the maximum tolerated dose (MTD), recommended Phase 2 dose(RP2D),safety & tolerability of BGB-10188: as monotherapy in participants with mature B-cell malignancies; oin combination with zanubrutinib in participants with relapse/refractory follicular lymphoma (R/R FL), mantle cell lymphoma (MCL) or diffuse large B-cell lymphoma …
- 0 views
- 19 Feb, 2024
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
This is a phase I, open-label, non-randomized study that will enroll pediatric and young adult research participants with relapsed or refractory non-CNS solid tumors to evaluate the safety, feasibility, and efficacy of administering T cell products derived from the research participant's blood that have been genetically modified to express a …
- 0 views
- 19 Feb, 2024
Tipifarnib for the Treatment of Advanced Solid Tumors Lymphoma or Histiocytic Disorders With HRAS Gene Alterations a Pediatric MATCH Treatment Trial
This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have HRAS genetic alterations. Tipifarnib may block the growth of cancer cells that have specific genetic changes in …
- 0 views
- 19 Feb, 2024
PET/CT Whole-body Dynamic Acquisition at FDG to Metastatic Melanoma Under Immunotherapy
The value of 4D body-to-whole dynamic acquisition in FDG PET / CT to differentiate progression / pseudo-progression during the first therapeutic assessment (PET1) of metastatic melanoma treated with immune checkpoint inhibitors (ICI)to predict the progression of the disease..
- 0 views
- 19 Feb, 2024
Understanding the Transition from Normal Melanocytes to Nevus to Melanoma (NevustoMel)
The primary objective of this study is to identify the molecular identity profiles of all cellular states that characterize the progression from benign nevi to malignant melanoma in CAYA patients with L/GCMN. The secondary objectives are:To longitudinally characterize the cell-free DNA (cfDNA) from CAYA patients.
- 0 views
- 06 Feb, 2025
Serial Tumour Biopsies and Blood Biomarkers in Melanoma
The overall aim of this study will be to collect tumour biopsies, biomarkers present in the blood, and other biological specimens which can be used to try to understand why resistance to anti-cancer treatment occurs, and to develop predictive biomarkers of this resistance in patients with locally advanced and metastatic …
- 0 views
- 19 Feb, 2024
Patient Reported Outcome Measures After Treatment of Skin Cancers on the Face
This study is to evaluate the psychological well-being in patients diagnosed with skin cancer (melanoma and Squamous Cell Carcinoma (SCC) in the face) at the time of diagnosis and after treatment. Patients diagnosed with primary melanoma and/or SCC and/or infiltrative basal cell carcinoma on the face subjected to surgical treatment …
- 0 views
- 19 Feb, 2024
- 1
- 2